Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Tue., Apr. 23, 4:43 AM
Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.
| This Slide: #92 of 100 |
Slide #92. AstraZeneca — Pearl Therapeutics
Acquirer:
AstraZeneca (NASDAQ:AZN)
Acquiree:
Pearl Therapeutics
Details:
Pearl Therapeutics Inc. today announced that it has entered into a definitive merger agreement under which the Company will be acquired by AstraZeneca. The acquisition will bring together Pearl's pipeline of inhaled bronchodilator products for the treatment of patients with COPD and AstraZeneca's core capabilities in respiratory disease. The transaction was unanimously approved by the boards of directors of both companies.
AstraZeneca is a holding company. Through its subsidiaries, Co. is engaged in pharmaceutical business focusing on the research, development, manufacturing and commercialization of prescription medicines. Co. is focused on its therapy areas: Oncology, which provides Tagrisso (osimertinib) for lung cancer; BioPharmaceuticals, which provides Farxiga/ Forxiga (dapagliflozin) for Type-2 diabetes, heart failure with reduced ejection fraction and chronic kidney disease; and Rare Disease, which provides Soliris (eculizumab) for paroxysmal nocturnal haemoglobinuria, atypical haemolytic uraemic syndrome, generalised myasthenia gravis and neuromyelitis optica spectrum disorder.
Open the AZN Page at The Online Investor »
|
|||||||||||||||||||||
Open the AZN Page at The Online Investor (in a new window) »
 Free AZN Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
 
|
Buy (3.41 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: AZN Stock Forecast Based on Zacks ABR data; powered by Xignite |
